[10-K/A] Northann Corp. Amends Annual Report
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Panoramica della dichiarazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite la tranche finale di un premio RSU basato sulle performance del 16 marzo 2023. Per soddisfare le imposte da trattenere, la società ha venduto automaticamente 85.596 azioni a 2,79 $ ciascuna. Dopo questa vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un incremento di circa 132 mila azioni rispetto al saldo precedente.
- Natura della transazione: Il codice “A” indica l’acquisizione tramite premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una compravendita sul mercato aperto.
- Base di costo: Le RSU sono state liquidate senza costi in contanti per l’insider; solo la vendita per il pagamento delle tasse ha un prezzo di mercato.
- Impatto sull’allineamento: L’esecutivo mantiene una partecipazione azionaria significativa (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in denaro.
In sintesi, la dichiarazione riflette una normale maturazione di compensi azionari e la relativa trattenuta fiscale, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale salvo altri eventi.
Resumen de presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, listado como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir las retenciones fiscales, la empresa vendió automáticamente 85,596 acciones a 2.79 $ por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132 mil acciones respecto al saldo anterior.
- Naturaleza de la transacción: El código “A” indica adquisición por premio de acciones; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
- Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta para impuestos tiene precio de mercado.
- Impacto en alineación: El ejecutivo mantiene una participación accionaria significativa (aprox. 3.3 millones de acciones), reforzando la alineación de incentivos, pero no hubo nueva inversión en efectivo.
En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la correspondiente retención fiscal, más que una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.
Form 4 제출 개요: Clover Health Investments (CLOV)는 ‘Medicare Advantage CEO’로 등재된 Jamie L. Reynoso의 내부자 거래를 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 보상의 마지막 분할로 217,523주 클래스 A 주식을 취득했습니다. 원천징수 세금을 충당하기 위해 회사는 자동으로 85,596주를 주당 2.79달러에 매도했습니다. 자동 매도 후 Reynoso 씨의 직접 보유 주식은 3,328,328주 클래스 A로 이전 잔액 대비 약 13만 2천 주 증가했습니다.
- 거래 성격: “A” 코드는 주식 수상에 따른 취득, “F” 코드는 세금 원천징수를 위한 주식 보유를 의미하며, 둘 다 공개 시장 거래는 아닙니다.
- 원가 기준: RSU는 내부자에게 현금 비용 없이 정산되었으며, 세금 원천징수를 위한 매도만 시장 가격이 적용되었습니다.
- 정렬 영향: 경영진은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화했으나, 신규 현금 투자는 없었습니다.
전반적으로 이번 제출은 임의의 매수 또는 매도 결정이 아닌, 정기적인 주식 보상 성숙 및 세금 원천징수를 반영합니다. 다른 촉매가 없으면 시장 영향은 중립적일 것으로 예상됩니다.
Présentation du formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de classe A lors de la dernière tranche d’une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de classe A, soit environ 132 000 actions de plus que précédemment.
- Nature de la transaction : Le code « A » indique une acquisition via attribution d’actions ; le code « F » des actions retenues pour impôts — aucune des deux n’est une transaction sur le marché libre.
- Base de coût : Les RSU ont été réglées sans coût en espèces pour l’initié ; seule la vente liée à la retenue fiscale est au prix du marché.
- Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en espèces n’a été effectué.
Globalement, le dépôt reflète un vesting habituel de compensation en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre, sauf autres catalyseurs.
Übersicht zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insider-Aktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, etwa 132.000 Aktien mehr als zuvor.
- Art der Transaktion: Code „A“ steht für Erwerb durch Aktienzuteilung; Code „F“ für zurückbehaltene Aktien zur Steuerzahlung – beides keine offenen Markttransaktionen.
- Kostenbasis: Die RSUs wurden ohne Barzahlung für den Insider abgewickelt; nur der steuerbedingte Verkauf erfolgte zum Marktpreis.
- Auswirkung auf Ausrichtung: Die Führungskraft hält eine bedeutende Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Barinvestition getätigt.
Insgesamt spiegelt die Einreichung eine routinemäßige Aktienvergütung und die damit verbundene Steuerabführung wider, keine diskretionäre Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Ereignisse eintreten.
- Executive ownership rises by ~132,000 shares, increasing alignment with shareholders.
- Performance-based vesting suggests the company met or exceeded predefined targets tied to the 2023 RSU grant.
- None.
Insights
TL;DR: Routine RSU vesting—neutral impact; insider’s stake increases, no open-market buying.
The 217.5 k share addition arises from a scheduled performance-based RSU vesting. The automatic 85.6 k-share sale merely covers payroll taxes. Net beneficial ownership growth of ~132 k shares (≈4 % of her prior holdings) is not large enough to signal a strong incremental vote of confidence, but it modestly enhances alignment. Because there is no discretionary purchase or sale, I view the filing as informational, not directional. Trading volume impact should be minimal.
TL;DR: Performance-based vesting confirms compensation plan progression; governance concerns minimal.
The disclosure shows Clover Health’s incentive structure functioning as designed: shares vest only after performance hurdles, with automatic tax withholding to avoid insider liquidity strain. The executive’s continued sizable ownership (3.3 M shares) exceeds common ownership guidelines, fostering shareholder alignment. There are no indications of problematic timing, 10b5-1 usage, or unusual dispositions. Therefore, the governance signal is neutral-to-slightly-positive, but not materially impactful to valuation.
Panoramica della dichiarazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite la tranche finale di un premio RSU basato sulle performance del 16 marzo 2023. Per soddisfare le imposte da trattenere, la società ha venduto automaticamente 85.596 azioni a 2,79 $ ciascuna. Dopo questa vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un incremento di circa 132 mila azioni rispetto al saldo precedente.
- Natura della transazione: Il codice “A” indica l’acquisizione tramite premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una compravendita sul mercato aperto.
- Base di costo: Le RSU sono state liquidate senza costi in contanti per l’insider; solo la vendita per il pagamento delle tasse ha un prezzo di mercato.
- Impatto sull’allineamento: L’esecutivo mantiene una partecipazione azionaria significativa (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in denaro.
In sintesi, la dichiarazione riflette una normale maturazione di compensi azionari e la relativa trattenuta fiscale, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale salvo altri eventi.
Resumen de presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, listado como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir las retenciones fiscales, la empresa vendió automáticamente 85,596 acciones a 2.79 $ por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132 mil acciones respecto al saldo anterior.
- Naturaleza de la transacción: El código “A” indica adquisición por premio de acciones; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
- Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta para impuestos tiene precio de mercado.
- Impacto en alineación: El ejecutivo mantiene una participación accionaria significativa (aprox. 3.3 millones de acciones), reforzando la alineación de incentivos, pero no hubo nueva inversión en efectivo.
En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la correspondiente retención fiscal, más que una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.
Form 4 제출 개요: Clover Health Investments (CLOV)는 ‘Medicare Advantage CEO’로 등재된 Jamie L. Reynoso의 내부자 거래를 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 보상의 마지막 분할로 217,523주 클래스 A 주식을 취득했습니다. 원천징수 세금을 충당하기 위해 회사는 자동으로 85,596주를 주당 2.79달러에 매도했습니다. 자동 매도 후 Reynoso 씨의 직접 보유 주식은 3,328,328주 클래스 A로 이전 잔액 대비 약 13만 2천 주 증가했습니다.
- 거래 성격: “A” 코드는 주식 수상에 따른 취득, “F” 코드는 세금 원천징수를 위한 주식 보유를 의미하며, 둘 다 공개 시장 거래는 아닙니다.
- 원가 기준: RSU는 내부자에게 현금 비용 없이 정산되었으며, 세금 원천징수를 위한 매도만 시장 가격이 적용되었습니다.
- 정렬 영향: 경영진은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화했으나, 신규 현금 투자는 없었습니다.
전반적으로 이번 제출은 임의의 매수 또는 매도 결정이 아닌, 정기적인 주식 보상 성숙 및 세금 원천징수를 반영합니다. 다른 촉매가 없으면 시장 영향은 중립적일 것으로 예상됩니다.
Présentation du formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de classe A lors de la dernière tranche d’une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de classe A, soit environ 132 000 actions de plus que précédemment.
- Nature de la transaction : Le code « A » indique une acquisition via attribution d’actions ; le code « F » des actions retenues pour impôts — aucune des deux n’est une transaction sur le marché libre.
- Base de coût : Les RSU ont été réglées sans coût en espèces pour l’initié ; seule la vente liée à la retenue fiscale est au prix du marché.
- Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en espèces n’a été effectué.
Globalement, le dépôt reflète un vesting habituel de compensation en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre, sauf autres catalyseurs.
Übersicht zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insider-Aktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, etwa 132.000 Aktien mehr als zuvor.
- Art der Transaktion: Code „A“ steht für Erwerb durch Aktienzuteilung; Code „F“ für zurückbehaltene Aktien zur Steuerzahlung – beides keine offenen Markttransaktionen.
- Kostenbasis: Die RSUs wurden ohne Barzahlung für den Insider abgewickelt; nur der steuerbedingte Verkauf erfolgte zum Marktpreis.
- Auswirkung auf Ausrichtung: Die Führungskraft hält eine bedeutende Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Barinvestition getätigt.
Insgesamt spiegelt die Einreichung eine routinemäßige Aktienvergütung und die damit verbundene Steuerabführung wider, keine diskretionäre Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Ereignisse eintreten.
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
SC | |
(Address of principal executive offices) | (Zip Code) |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
Large accelerated filer | | Accelerated filer | | |
| Smaller reporting company | |||
Emerging growth company |
ITEM 8. |
FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA |
2 |
ITEM 15. |
EXHIBITS, FINANCIAL STATEMENTS, SCHEDULES |
Exhibit Number |
|
Description |
3.1
|
Articles of Incorporation (incorporated by reference to Exhibit 3.1 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
3.2
|
|
Certificate of Amendment to the Articles of Incorporation (incorporated by reference to Exhibit 3.2 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
3.3
|
Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.3 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
3.4
|
Certificate of Amendment to the Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.4 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
3.5
|
Bylaws (incorporated by reference to Exhibit 3.5 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
4.5
|
Description of Securities (incorporated by reference to Exhibit 4.5 of our Annual Report on Form 10-K (File No. 001-41816), filed with the Securities and Exchange Commission on July 1, 2025)
|
|
10.1
|
Employment Agreement between the Company and Lin Li dated July 1, 2022 (incorporated by reference to Exhibit 10.2 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
10.2
|
Employment Agreement between the Company and Kurtis W. Winn dated July 1, 2022 (incorporated by reference to Exhibit 10.4 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
10.3
|
English translation of the Construction Agreement between NCP and Changzhou Wanyuan Construction Engineering Co., dated July 26, 2021 (incorporated by reference to Exhibit 10.12 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
10.4
|
|
English Translation of Form of Loan Agreement by and between NCP and Industrial and Commercial Bank of China dated June 4, 2024 (Contract No. 2024 (Wujin) Zi 00690) (incorporated by reference to Exhibit 10.4 of our Registration Statement on Form S-1 (File No. 333-284033), as amended, initially filed with the Securities and Exchange Commission on January 14, 2025)
|
10.5
|
|
English Translation of Form of Loan Agreement by and between NCP and Industrial and Commercial Bank of China dated June 4, 2024 (Contract No. 2024 (Wujin) Zi 00957) (incorporated by reference to Exhibit 10.5 of our Registration Statement on Form S-1 (File No. 333-284033), as amended, initially filed with the Securities and Exchange Commission on January 14, 2025)
|
10.6
|
|
English Translation of Loan Agreement by and between NCP and Jiangnan Rural Commercial Bank entered on March 26, 2020 (incorporated by reference to Exhibit 10.6 of our Registration Statement on Form S-1 (File No. 333-284033), as amended, initially filed with the Securities and Exchange Commission on January 14, 2025)
|
10.7
|
2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
10.8
|
Lease Agreement, dated July 26, 2024 and amended as of August 5, 2024, among Northann Corp. and SKY SC LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on August 5, 2024)
|
3 |
10.9
|
Share Purchase Agreement, dated as of October 11, 2024, by and between Northann Corp .and Chuntao Li (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on October 15, 2024)
|
|
10.10
|
Share Purchase Agreement by and between the Company and Jianquan Xu dated November 13, 2024 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on November 15, 2024)
|
|
10.11
|
First Amendment of Lease, dated November 19, 2024, among Northann Corp. and SKY SC LLC (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed with the SEC on November 21, 2024)
|
|
10.12
|
Financing and Strategic Planning Advisory Agreement by and between the Company and Linkun Investment LLC dated December 4, 2024 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on December 5, 2024)
|
|
10.13
|
Business Development Agreement by and between the Company and CAKL Holdings Sdn Bhd dated December 4, 2024 (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed with the SEC on December 5, 2024)
|
|
|
|
|
10.14 |
Technical Service Agreement by and between the Company and San River International Sdn Bhd dated December 4, 2024 (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K filed with the SEC on December 5, 2024) |
|
10.15
|
Form of Share Purchase Agreement by and between the Company and Oneflow LLC as the lead investor and other investors dated December 6, 2024 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on December 6, 2024)
|
|
10.16 |
Form of Registration Rights Agreement by and between the Company and Oneflow LLC as the lead investor and other investors dated December 6, 2024 (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed with the SEC on December 6, 2024) |
|
10.17
|
Form of Share Purchase Agreement by and between the Company and X29 LLC as the lead investor and other investors dated December 6, 2024 (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K filed with the SEC on December 6, 2024)
|
|
10.18 |
Form of Registration Rights Agreement by and between the Company and X29 LLC as the lead investor and other investors dated December 6, 2024 (incorporated by reference to Exhibit 10.4 of our Current Report on Form 8-K filed with the SEC on December 6, 2024) |
|
10.19
|
Form of Share Purchase Agreement by and between the Company and Caitlin Xu Kang as the lead investor and other investors dated December 20, 2024 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on December 23, 2024)
|
|
10.20 |
EB-5 Loan Agreement dated January 21, 2025, between 3D PRINTING DEV, LLC and 3DFLOR OPPORTUNITY, LP (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on March 5, 2025) |
|
10.21
|
Promissory Note issued by 3D PRINTING DEV, LLC on January 27, 2025 (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed with the SEC on March 5, 2025)
|
|
10.22 |
Membership Interest Pledge Agreement dated January 27, 2025, by and among Benchwick LLC, 3DFLOR OPPORTUNITY, LP and 3D PRINTING DEV, LLC (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K filed with the SEC on March 5, 2025) |
|
14.1
|
Code of Business Conduct and Ethics of the Company (incorporated by reference to Exhibit 10.16 of our Registration Statement on Form S-1 File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
14.2 |
|
Insider Trading Policy (incorporated by reference to Exhibit 14.2 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023) |
21.1
|
List of Subsidiaries (incorporated by reference to Exhibit 21.1 of our Annual Report on Form 10-K (File No. 001-41816), filed with the Securities and Exchange Commission on July 1, 2025)
|
|
23.1
|
Consent of WWC, P.C. (incorporated by reference to Exhibit 23.1 of our Annual Report on Form 10-K (File No. 001-41816), filed with the Securities and Exchange Commission on July 1, 2025)
|
|
23.2
|
Consent of LAO Professionals(incorporated by reference to Exhibit 23.2 of our Annual Report on Form 10-K (File No. 001-41816), filed with the Securities and Exchange Commission on July 1, 2025)
|
4 |
31.1*
|
Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer
|
|
31.2*
|
Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer
|
|
32.1*
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2*
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
97.1
|
Clawback Policy (incorporated by reference to Exhibit 97.1 of our Annual Report on Form 10-K filed with the SEC on April 15, 2024)
|
|
99.1
|
Audit Committee Charter (incorporated by reference to Exhibit 99.2 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
99.2
|
Nominating Committee Charter (incorporated by reference to Exhibit 99.3 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
99.3
|
Compensation Committee Charter (incorporated by reference to Exhibit 99.44 of our Registration Statement on Form S-1 (File No. 333-273246), as amended, initially filed with the Securities and Exchange Commission on July 14, 2023)
|
|
101.INS * |
|
XBRL INSTANCE DOCUMENT |
101.SCH * |
|
XBRL TAXONOMY EXTENSION SCHEMA |
101.CAL * |
|
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE |
101.DEF * |
|
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE |
101.LAB * |
|
XBRL TAXONOMY EXTENSION LABEL LINKBASE |
101.PRE * |
|
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE |
* |
Filed herewith |
5 |
NORTHANN CORP. |
||
|
|
|
Dated: July 2, 2025 |
By: |
/s/ Lin Li |
|
|
Lin Li |
|
|
Chairman of the Board, Chief Executive Officer, President, Secretary, and Treasurer |
6 |
Consolidated Financial Statements for the Fiscal Years Ended December 31, 2024 and 2023 |
|
|
|
Reports of Independent Registered Accounting Firm
|
F-2
|
|
|
Consolidated Balance Sheets as of December 31, 2024 and 2023
|
F-4
|
|
|
Consolidated Statements of Income and Comprehensive Income (Loss) for the Years Ended December 31, 2024 and 2023
|
F-5
|
|
|
Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2024 and 2023
|
F-6
|
|
|
Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
|
F-7
|
|
|
Notes to Consolidated Financial Statements
|
F-8
|
F-1 |
/S/ Lateef Awojobi |
|
LAO PROFESSIONALS |
|
(PCAOB ID 7057) |
|
Lagos, Nigeria |
|
F-2 |
To: |
The Board of Directors and Stockholders of Northann Corp. |

F-3 |
202 4 | 202 3 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash | $ | $ | ||||||
Restricted cash | ||||||||
Accounts receivable, net | ||||||||
Inventory, net | ||||||||
Prepayments | ||||||||
Other receivables and other current assets | ||||||||
Total current assets | ||||||||
NON-CURRENT ASSETS | ||||||||
Property, plant and equipment, net | ||||||||
Construction in progress | ||||||||
Intangible assets , net | ||||||||
Operating lease right-of-use assets, net | ||||||||
Security deposits | ||||||||
Total non-current assets | ||||||||
TOTAL ASSETS | $ | $ | ||||||
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
CURRENT LIABILITIES | ||||||||
Bank borrowings - current | ||||||||
Operating lease liabilities, current | ||||||||
Accounts and other payables and accruals | ||||||||
Taxes payable | ||||||||
Unearned revenue | ||||||||
Amounts due to related parties | ||||||||
Obligation under secured borrowing arrangement | ||||||||
Total current liabilities | ||||||||
Bank borrowings – non-current | ||||||||
Operating lease liabilities, – non-current | ||||||||
Total non-current liabilities | ||||||||
TOTAL LIABILITIES | $ | $ | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
Preferred stock, 4 and 202 3 * | ||||||||
Common stock, $ 4 and 202 3 , respectively* | ||||||||
Subscription receivable | ( | ) | ( | ) | ||||
Accrued compensation expense | ( | ) | ||||||
Additional paid-in capital | ||||||||
Accumulated deficits | ( | ) | ( | ) | ||||
Accumulated other comprehensive loss | ( | ) | ||||||
Total stockholders’ equity | ||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ |
* | Retrospectively restated for the effect of (Note 1 8 ) |
F-4 |
|
|
202 4 |
|
|
202 3 |
|
||
|
|
|
|
|
|
|
||
REVENUES |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
COST OF REVENUES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GROSS PROFIT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
Selling expenses |
|
|
|
|
|
|
|
|
General and administrative expenses |
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE) |
|
|
|
|
|
|
|
|
Interest expense |
|
|
( |
) |
|
|
( |
) |
Amortization of debt discounts |
|
|
|
|
|
|
( |
) |
Other income |
|
|
|
|
|
|
|
|
Other expenses |
|
|
( |
) |
|
|
|
|
Impairment loss on goodwill |
|
|
( |
) |
|
|
|
|
Interest income |
|
|
|
|
|
|
|
|
Total other expenses , net |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
LOSS BEFORE TAXES |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
Income tax expense |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
NET LOSS |
|
|
( |
) |
|
|
( |
)
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
Total comprehensive loss |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
|
|
|
|
|
|
|
Weighted average number of shares of common stock outstanding – basic |
|
|
|
|
|
|
|
|
Weighted average number of shares of common stock outstanding –diluted |
|
|
|
|
|
|
|
|
F-5 |
|
|
Preferred Stock – |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Series A |
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
Number of shares* |
|
|
Amount |
|
|
Number of shares* |
|
|
Amount |
|
|
Subscription receivable |
|
|
Additional paid in capital |
|
|
Retained earnings |
|
|
Accumulated other comprehensive loss |
|
|
Total |
|
|||||||||
Balance, December 31, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
( |
) |
|
|
- |
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
|
|
Issuance of ordinary shares upon the completion of the IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acc ru ed compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
* |
Retrospectively restated for the effect of (Note 1 8 ) |
F-6 |
|
|
202 4 |
|
|
202 3 |
|
||
|
|
|
|
|
|
|
||
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
Adjustments to reconcile net loss to cash (used in) provided by operating activities: |
|
|
|
|
|
|
|
|
Allowance for doubtful accounts |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
Impairment of Property, plant and equipment |
|
|
|
|
|
|
|
|
Inventory write down |
|
|
|
|
|
|
|
|
Impairment of goodwill |
|
|
|
|
|
|
|
|
I ncome fr om settlement of convertible notes |
|
|
( |
) |
|
|
|
|
Share-based compensation |
|
|
|
|
|
|
|
|
Changes in assets and liabilities |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
( |
) |
|
|
( |
) |
Other receivables |
|
|
|
|
|
|
( |
) |
Prepayments |
|
|
( |
) |
|
|
( |
) |
Inventory |
|
|
|
|
|
|
|
|
Right of use assets |
|
|
( |
) |
|
|
( |
) |
Accounts payable |
|
|
( |
) |
|
|
( |
) |
Accruals and other payables |
|
|
( |
) |
|
|
|
|
Unearned revenue |
|
|
( |
) |
|
|
|
|
Payroll payable |
|
|
|
|
|
|
|
|
Taxes payable |
|
|
( |
) |
|
|
|
|
Accrued interest |
|
|
|
|
|
|
|
|
Operating leases |
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Payments for construction |
|
|
( |
) |
|
|
|
|
Net cash used in investing activities |
|
|
( |
) |
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from bank borrowings |
|
|
|
|
|
|
|
|
Payment of Bank Loan |
|
|
( |
) |
|
|
( |
) |
Amount received from secured borrowing arrangement |
|
|
- |
|
|
|
|
|
Payment of secured borrowing arrangement |
|
|
( |
) |
|
|
- |
|
Settlement of convertible notes |
|
|
( |
) |
|
|
- |
|
Amounts received from related party |
|
|
|
|
|
|
|
|
Net proceeds from issuance of ordinary shares upon IPO |
|
|
- |
|
|
|
|
|
Net cash (used in) provided by financing activities |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and restricted cash |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and restricted cash at beginning of year |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and restricted cash at end of year |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Supplemental of cash flow information |
|
|
|
|
|
|
|
|
Cash paid for interest expenses |
|
$ |
|
|
|
$ |
|
|
Cash paid for income tax |
|
$ |
|
|
|
$ |
|
|
F-7 |
1. | ORGANIZATION AND BUSINESS |
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
F-8 |
F-9 |
F-10 |
Balance sheet items, except for equity accounts | ||||||||
December 31, 202 4 | RMB to $ | HKD to $ | ||||||
December 31, 202 3 | RMB to $ | HKD to $ | ||||||
Income statement and cash flows items | ||||||||
For the year ended December 31, 202 4 | RMB to $ | HKD to $ | ||||||
For the year ended December 31, 2023 | RMB | HKD to $ |
F-11 |
Estimated useful lives (years) | ||||
Office and computer equipment | ||||
Manufacturing equipment |
Estimated useful lives (years) | ||||
Land use right |
F-12 |
202 4 | 202 3 | |||||||
Net loss | $ | ( | ) | $ | ( | ) | ||
Weighted average number of shares of common stock outstanding - basic * | ||||||||
Add: potentially dilutive effect of shares issuable upon exercise of warrants | ||||||||
Weighted average number of shares of common stock outstanding - diluted * | ||||||||
Net loss per ordinary share | ||||||||
-Basic | $ | ( | ) | $ | ( | ) | ||
-Diluted | $ | ( | ) | $ | ( | ) |
F-13 |
F-14 |
F-15 |
3. | BUSINESS COMBINATION |
Amount | ||||
US$ | ||||
Amount due from related party | ||||
Total identifiable assets acquired | ||||
Total liabilities assumed | ||||
Net identifiable assets acquired | ||||
Number of Class A ordinary shares issued as consideration | ||||
Quoted price of Class A ordinary shares on acquisition date | ||||
Total purchase consideration | ||||
Goodwill |
Amount | ||||
US$ | ||||
Amount due from related party | ||||
Total identifiable assets acquired | ||||
Total liabilities assumed | ||||
Net identifiable assets acquired | ||||
Number of Class A ordinary shares issued as consideration | ||||
Quoted price of Class A ordinary shares on acquisition date | ||||
Total purchase consideration | ||||
Goodwill |
F-16 |
4 . |
RESTRICTED CASH |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
Deposit for Bank acceptance bill |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
|
|
|
$ |
|
|
5 . |
ACCOUNTS RECEIVABLE, NET |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
Gross accounts receivable |
|
$ |
|
|
|
$ |
|
|
Total |
|
$ |
|
|
|
$ |
|
|
F-17 |
6 . |
OTHER RECEIVABLES |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
|
|
|
|
|
|
|
||
Deposit and other receivables |
|
|
|
|
|
|
|
|
Total |
|
$ |
|
|
|
$ |
|
|
7 . |
INVENTORY, NET |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
Raw materials and components |
|
$ |
|
|
|
$ |
|
|
Finished goods |
|
|
|
|
|
|
|
|
Inventories, net |
|
$ |
|
|
|
$ |
|
|
8 . |
EQUIPMENT, NET |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
|
|
|
|
|
|
|
||
Manufacturing equipment |
|
|
|
|
|
|
|
|
Office equipment |
|
|
|
|
|
|
|
|
L ess: Accumulated depreciation |
|
|
|
|
|
|
|
|
Total |
|
$ |
|
|
|
$ |
|
|
9 . |
INTANG IBLE ASSETS , NET |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
|
|
|
|
|
|
|
||
Land use right |
|
$ |
|
|
|
$ |
|
|
Software |
|
|
|
|
|
|
|
|
less: Accumulated amortization |
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
F-18 |
10 . | BANK BORROWINGS |
Bank | Loan period | Interest rate | Balance at December 31, 2024 | Balance at December 31, 2023 | ||||||||||||
Industrial and Commercial Bank of China | % | $ | $ | |||||||||||||
Industrial and Commercial Bank of China | % | |||||||||||||||
Industrial and Commercial Bank of China | % | |||||||||||||||
Industrial and Commercial Bank of China | 0 , 2025 | % | ||||||||||||||
Bank of Communications | % | |||||||||||||||
Bank of Communications | % | |||||||||||||||
BANK OF AMERICA - Line of Credit | Prime rate + | |||||||||||||||
Jiangnan Rural Commercial Bank | % | |||||||||||||||
Jiangnan Rural Commercial Bank | % | |||||||||||||||
Jiangnan Rural Commercial Bank | % | |||||||||||||||
Agricultural Bank of China, Changzhou Zhonglou Sub-branch | % | |||||||||||||||
Total | $ | $ |
Bank | Loan period | Interest rate | Balance at December 31, 202 4 | Balance at December 31, 202 3 | ||||||||||||
EIDL Loan | From | % | ||||||||||||||
Total | $ | $ |
F-19 |
1 1 . | BALANCES WITH RELATED PARTY |
1) | Related party transactions |
2) | Related party balances |
Accounts | Name of Related Party | Note | December 31, 202 4 | December 31, 202 3 | ||||||||||||
Amount due to related party | Lin Li, Chief Executive Officer and Chairman of the Board | $ | $ |
1 2 . | EQUITY |
1 3 | INCOME TAXES |
F-20 |
|
|
For the year ended December 31, 202 4 |
|
|
For the year ended December 31, 202 3 |
|
||
Current: |
|
|
|
|
|
|
|
|
Federal |
|
$ |
|
|
|
$ |
|
|
State |
|
|
( |
) |
|
|
|
|
Foreign |
|
|
|
|
|
|
|
|
Total current |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Deferred: |
|
|
|
|
|
|
|
|
Federal |
|
$ |
|
|
|
$ |
|
|
State |
|
|
|
|
|
|
|
|
Foreign |
|
|
|
|
|
|
|
|
Total deferred |
|
$ |
|
|
|
$ |
|
|
Total income tax expense |
|
$ |
|
|
|
$ |
|
|
F-21 |
|
|
For the year ended December 31, 202 4 |
|
|
For the year ended December 31, 202 3 |
|
||
Loss before income tax expense |
|
$ |
( |
) |
|
$ |
( |
) |
Computed tax benefit with statutory tax rate |
|
|
|
% |
|
|
|
% |
Income tax expense computed at statutory income tax rate |
|
|
( |
) |
|
|
( |
) |
Impact of different tax rates in other jurisdictions |
|
|
|
|
|
|
|
|
Tax effect of non-deductible expenses |
|
|
|
|
|
|
|
|
Total income tax expense |
|
$ |
|
|
|
$ |
|
|
F-22 |
1 4 . |
CHINA CONTRIBUTION PLAN |
1 5 . |
OPERATING LEASE |
Assets/liabilities |
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
Assets |
|
|
|
|
|
|
|
|
Operating lease right-of-use assets |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
Operating lease liability - current |
|
$ |
|
|
|
$ |
|
|
Operating lease liability - non-current |
|
|
|
|
|
|
|
|
Total lease liabilities |
|
$ |
|
|
|
$ |
|
|
F-23 |
Lease Cost |
|
Classification |
|
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
|||
Operating lease expense |
|
|
General and administrative |
|
|
$ |
|
|
|
$ |
|
|
Maturity of Lease Liabilities |
|
Operating Leases |
|
|
12 months ending December 31, |
|
|
|
|
202 5 |
|
$ |
|
|
202 6 |
|
|
|
|
202 7 |
|
$ |
|
|
2028 |
|
|
|
|
202 9 |
|
|
|
|
Total lease payments |
|
$ |
|
|
Less: interest |
|
|
( |
) |
Present value of lease payments |
|
$ |
|
|
12 months ending December 31, |
|
|
|
|
202 4 |
|
$ |
|
|
2025 |
|
|
|
|
2026 |
|
|
|
|
Total lease payments |
|
$ |
|
|
Lease Term and Discount Rate |
|
December 31, 202 4 |
|
|
December 31, 202 3 |
|
||
Weighted-average remaining lease term (years) |
|
|
|
|
|
|
|
|
Operating leases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average discount rate (%) |
|
|
|
|
|
|
|
|
Operating leases |
|
|
|
% |
|
|
|
% |
1 6 . |
CONCENTRATIONS AND CREDIT RISK |
(a) |
Concentrations |
F-24 |
(b) | Credit risk |
1 7 . | COMMITMENTS AND CONTINGENCIES |
1 8 . | STOCK SPLIT |
1 9 . | SECURED BORROWING ARRANGEMENT |
F-25 |
20. | SUBSEQUENT EVENT |
F-26 |
2 1 . | UNRESTRICTED NET ASSETS |
As of December 31, | ||||||||
202 4 | 202 3 | |||||||
Cash | ||||||||
Amounts due from subsidiaries | ||||||||
Total current assets | ||||||||
All other non-current assets | ||||||||
Interests in a subsidiary | ||||||||
Total Assets | ||||||||
Liabilities and Stockholders’ Deficit | ||||||||
All other current liabilities | ||||||||
Amounts due to subsidiaries | ||||||||
Total current liabilities | ||||||||
Non-current liabilities | ||||||||
Total Liabilities | ||||||||
Stockholders’ Equity (Deficit) | ||||||||
Preferred stock,100,000,000 shares authorized – Series A, $ 2024 and 2023 * | ||||||||
Common stock, $ shares issued and outstanding as of December 31, 2024 and 2023 , respectively* | ||||||||
Subscription receivable | ( | ) | ( | ) | ||||
Additional Paid-in Capital | ||||||||
Accrued compensation expense | ( | ) | - | |||||
(Accumulated deficit) re tained earnings | ( | ) | ( | ) | ||||
Accumulated other comprehensive loss | ( | ) | ||||||
Total Stockholders’ Equity | ||||||||
Total Liabilities and Stockholders’ Deficit |
* | Retrospectively restated for the effect of 8 ) |
F-27 |
For the years ended December 31, | ||||||||
202 4 | 202 3 | |||||||
Revenue | ||||||||
Cost or revenues | ||||||||
Operating expenses | ||||||||
Income taxes | ||||||||
L oss – Parent only | ( | ) | ( | ) | ||||
I ncome (loss) – Subsidiaries with unrestricted net assets | ( | ) | ||||||
Loss – Subsidiaries with restricted net assets | ( | ) | ( | ) | ||||
Net loss – Consolidated | ( | ) | ( | ) |
For the years ended December 31, | ||||||||
202 4 | 202 3 | |||||||
Cash used in operating activities | ( | ) | ( | ) | ||||
Cash used in investing activities | - | |||||||
Cash provided by financing activities | ||||||||
Net cash flows | ( | ) | ||||||
Beginning cash balance | ||||||||
Ending cash balance |
(i) | Basis of presentation |
(ii) | Restricted Net Assets |
F-28 |